Pharmacodynamic Interplay of the P2Y(1), P2Y(12), and TxA(2) Pathways in Platelets: the Potential of Triple Antiplatelet Therapy with P2Y(1) Receptor Antagonism

Overview

Journal Thromb Res

Date 2012 Dec 19

PMID 23245937

Citations 3

Authors

Julie H Oestreich

Suellen P Ferraris

Steven R Steinhubl

Wendell S Akers

Affiliations

Soon will be listed here.

Abstract

Introduction: Previous work suggests that the extent of platelet inhibition by P2Y(1) receptor antagonism may be underappreciated, particularly in the context of dual antiplatelet therapy with aspirin and clopidogrel.

Materials And Methods: Using P2Y(1), P2Y(12), and TxA(2) receptor antagonists individually and in combination, we assessed the incremental changes from baseline platelet reactivity in blood collected from healthy volunteers.

Results: The P2Y(1) receptor antagonist further inhibited platelet activation and aggregation in several assay conditions ex vivo when combined with P2Y(12) and/or TxA(2) receptor blockers. Collagen and TRAP-induced platelet aggregation measured by light transmittance aggregometry was inhibited to a greater extent with the triple combination relative to each of the antagonists alone. The triple combination of P2Y(1), P2Y(12), and TxA(2) receptor antagonists also significantly shifted adenosine diphosphate (ADP)-stimulated platelet glycoprotein IIb/IIIa receptor and P-selectin expression compared to individual or dual antagonists.

Conclusions: These results substantiate that additional platelet inhibition occurs with the triple combination of P2Y(1), P2Y(12), and TxA(2) receptor antagonists and support further testing of P2Y(1) receptor antagonists as an option for alternative, synergistic, or triple antiplatelet therapy.

Citing Articles

A Perspective on How Fibrinaloid Microclots and Platelet Pathology May be Applied in Clinical Investigations.

Pretorius E, Kell D Semin Thromb Hemost. 2023; 50(4):537-551.

PMID: 37748515 PMC: 11105946. DOI: 10.1055/s-0043-1774796.

ADP-Mediated Upregulation of Expression of CD62P on Human Platelets Is Critically Dependent on Co-Activation of P2Y1 and P2Y12 Receptors.

Anderson R, Theron A, Steel H, Nel J, Tintinger G Pharmaceuticals (Basel). 2020; 13(12).

PMID: 33255391 PMC: 7760858. DOI: 10.3390/ph13120420.

Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.

Oestreich J, Steinhubl S, Ferraris S, Loftin C, Akers W J Thromb Thrombolysis. 2014; 38(3):372-9.

PMID: 24510678 DOI: 10.1007/s11239-014-1058-5.

References

Suh J, Lee S, Park K, Lee H, Kang H, Koo B . Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy.... J Am Coll Cardiol. 2011; 57(3):280-9. DOI: 10.1016/j.jacc.2010.08.631. View

Jin J, Daniel J, Kunapuli S . Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998; 273(4):2030-4. DOI: 10.1074/jbc.273.4.2030. View

Storey R, Sanderson H, White A, May J, Cameron K, Heptinstall S . The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000; 110(4):925-34. DOI: 10.1046/j.1365-2141.2000.02208.x. View

ODonoghue M, Bhatt D, Wiviott S, Goodman S, Fitzgerald D, Angiolillo D . Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation. 2011; 123(17):1843-53. DOI: 10.1161/CIRCULATIONAHA.110.000786. View

Oestreich J, Steinhubl S, Ferraris S, Akers W . High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. Thromb Haemost. 2011; 105(5):927-30. DOI: 10.1160/TH10-09-0603. View

Angiolillo D, Schneider D, Bhatt D, French W, Price M, Saucedo J . Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012; 34(1):44-55. DOI: 10.1007/s11239-012-0737-3. View

Hechler B, Eckly A, Ohlmann P, Cazenave J, Gachet C . The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol. 1998; 103(3):858-66. DOI: 10.1046/j.1365-2141.1998.01056.x. View

Alexander J, Lopes R, James S, Kilaru R, He Y, Mohan P . Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365(8):699-708. DOI: 10.1056/NEJMoa1105819. View

Suzuki T, Obara Y, Moriya T, Nakata H, Nakahata N . Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function. FEBS Lett. 2011; 585(24):3978-84. DOI: 10.1016/j.febslet.2011.10.050. View

10.

Storey R, Newby L, Heptinstall S . Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001; 12(7):443-7. DOI: 10.1080/09537100120085450. View

11.

Nylander S, Mattsson C, Ramstrom S, Lindahl T . Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol. 2004; 142(8):1325-31. PMC: 1575192. DOI: 10.1038/sj.bjp.0705885. View

12.

Oestreich J, Holt J, Dunn S, Smyth S, Campbell C, Charnigo R . Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis. 2009; 20(3):207-13. PMC: 2801158. DOI: 10.1097/MCA.0b013e328329924b. View

13.

Mega J, Braunwald E, Wiviott S, Bassand J, Bhatt D, Bode C . Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011; 366(1):9-19. DOI: 10.1056/NEJMoa1112277. View

14.

Tricoci P, Huang Z, Held C, Moliterno D, Armstrong P, Van de Werf F . Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2011; 366(1):20-33. DOI: 10.1056/NEJMoa1109719. View

15.

Labarthe B, Babin J, Bryckaert M, Theroux P, Bonnefoy A . Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel. Br J Pharmacol. 2011; 166(1):221-31. PMC: 3415650. DOI: 10.1111/j.1476-5381.2011.01683.x. View

16.

Akers W, Oh J, Oestreich J, Ferraris S, Wethington M, Steinhubl S . Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2009; 50(1):27-35. DOI: 10.1177/0091270009344986. View

17.

Hollopeter G, Jantzen H, Vincent D, Li G, ENGLAND L, Ramakrishnan V . Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409(6817):202-7. DOI: 10.1038/35051599. View